X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 34.5 37.7 91.4% View Chart
P/BV x 5.2 3.5 149.6% View Chart
Dividend Yield % 1.0 0.1 708.4%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
IPCA LABS
Mar-17
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,768643 274.9%   
Low Rs1,186503 235.8%   
Sales per share (Unadj.) Rs346.1254.4 136.0%  
Earnings per share (Unadj.) Rs55.216.1 343.3%  
Cash flow per share (Unadj.) Rs73.329.8 246.2%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %0.90.2 543.1%  
Book value per share (Unadj.) Rs257.1194.6 132.1%  
Shares outstanding (eoy) m169.22126.20 134.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.32.3 189.5%   
Avg P/E ratio x26.835.7 75.1%  
P/CF ratio (eoy) x20.119.2 104.7%  
Price / Book Value ratio x5.72.9 195.1%  
Dividend payout %25.46.2 407.8%   
Avg Mkt Cap Rs m249,88772,300 345.6%   
No. of employees `00011.813.3 88.6%   
Total wages/salary Rs m9,9346,960 142.7%   
Avg. sales/employee Rs Th4,971.52,413.5 206.0%   
Avg. wages/employee Rs Th843.2523.2 161.2%   
Avg. net profit/employee Rs Th792.4152.4 519.8%   
INCOME DATA
Net Sales Rs m58,56932,106 182.4%  
Other income Rs m2,233226 989.4%   
Total revenues Rs m60,80232,332 188.1%   
Gross profit Rs m13,7734,448 309.7%  
Depreciation Rs m3,0691,730 177.5%   
Interest Rs m2,056241 853.7%   
Profit before tax Rs m10,8812,703 402.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545675 228.8%   
Profit after tax Rs m9,3362,028 460.3%  
Gross profit margin %23.513.9 169.7%  
Effective tax rate %14.225.0 56.9%   
Net profit margin %15.96.3 252.4%  
BALANCE SHEET DATA
Current assets Rs m53,84117,340 310.5%   
Current liabilities Rs m31,6129,559 330.7%   
Net working cap to sales %38.024.2 156.6%  
Current ratio x1.71.8 93.9%  
Inventory Days Days97100 96.9%  
Debtors Days Days8457 147.3%  
Net fixed assets Rs m42,07920,779 202.5%   
Share capital Rs m846252 335.3%   
"Free" reserves Rs m42,65524,499 174.1%   
Net worth Rs m43,50124,553 177.2%   
Long term debt Rs m22,4083,517 637.1%   
Total assets Rs m101,25039,595 255.7%  
Interest coverage x6.312.2 51.5%   
Debt to equity ratio x0.50.1 359.6%  
Sales to assets ratio x0.60.8 71.3%   
Return on assets %11.35.7 196.3%  
Return on equity %21.58.3 259.8%  
Return on capital %19.610.5 187.1%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m20,06615,617 128.5%   
Fx outflow Rs m5,3045,828 91.0%   
Net fx Rs m14,7629,790 150.8%   
CASH FLOW
From Operations Rs m10,1272,764 366.4%  
From Investments Rs m-7,869-1,432 549.6%  
From Financial Activity Rs m-1,918-1,591 120.5%  
Net Cashflow Rs m212-259 -81.7%  

Share Holding

Indian Promoters % 71.5 45.9 155.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.4 61.6%  
FIIs % 12.6 25.3 49.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.4 50.6%  
Shareholders   26,511 36,892 71.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 145 Points Up; Sun Pharma Rallies on Strong Earnings(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is flat while the Hang Seng is up 0.7%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 28, 2018 10:41 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - IPCA LABS COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS